{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:33Z","timestamp":1790915013903,"version":"4.1.0"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2018,11,20]]},"DOI":"10.1001\/jama.2018.15870","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T15:48:31Z","timestamp":1540568911000},"page":"2010","source":"Crossref","is-referenced-by-count":109,"title":["Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1001","volume":"320","author":[{"given":"Esther","family":"Meijer","sequence":"first","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"},{"name":"Department of Internal Medicine, Hospital Group Twente, Almelo, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene M. M.","family":"van Aerts","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Blijdorp","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F.","family":"Casteleijn","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig M. A.","family":"D\u2018Agnolo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shosha E. I.","family":"Dekker","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P. H.","family":"Drenth","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maatje D. A.","family":"van Gastel","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.","family":"Gevers","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten A.","family":"Lantinga","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Losekoot","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Lianne","family":"Messchendorp","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrte K.","family":"Neijenhuis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle J.","family":"Pena","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University, Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J. M.","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Human Genetics, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Salih","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Soonawala","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Department of Internal Medicine, Haga Teaching Hospital, The Hague, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Spithoven","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Wetzels","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zietse","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Center Groningen, University Hospital Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the DIPAK-1 Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9981","key":"joi180121r1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/S0140-6736(15)60907-2","article-title":"Autosomal dominant polycystic kidney disease: the changing face of clinical management.","volume":"385","author":"Ong","year":"2015","journal-title":"Lancet"},{"issue":"8","key":"joi180121r2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1093\/ndt\/gfw240","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union.","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"joi180121r3","doi-asserted-by":"publisher","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for ADPKD in Europe: prevalence and survival\u2014an analysis of data from the ERA-EDTA Registry.","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"joi180121r4","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1681\/ASN.2006020136","article-title":"Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease.","volume":"17","author":"Smith","year":"2006","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"joi180121r5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"joi180121r6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family.","volume":"20","author":"Patel","year":"1999","journal-title":"Front Neuroendocrinol"},{"issue":"1","key":"joi180121r7","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/0014-5793(86)81180-2","article-title":"Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells.","volume":"198","author":"Friedlander","year":"1986","journal-title":"FEBS Lett"},{"issue":"3","key":"joi180121r8","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"joi180121r9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"joi180121r10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1681\/ASN.2013121312","article-title":"Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.","volume":"26","author":"Hopp","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"joi180121r11","doi-asserted-by":"publisher","first-page":"e0177934","DOI":"10.1371\/journal.pone.0177934","article-title":"Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease.","volume":"12","author":"Kugita","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"joi180121r12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease.","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"issue":"6","key":"joi180121r14","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"joi180121r15","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1111\/liv.2015.35.issue-5","article-title":"Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.","volume":"35","author":"Gevers","year":"2015","journal-title":"Liver Int"},{"issue":"3","key":"joi180121r16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1053\/j.ajkd.2013.10.011","article-title":"Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.","volume":"63","author":"Meijer","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"joi180121r17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD.","volume":"20","author":"Pei","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"joi180121r18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate.","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"5","key":"joi180121r19","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1053\/j.ajkd.2015.06.017","article-title":"Estimation of total kidney volume in autosomal dominant polycystic kidney disease.","volume":"66","author":"Spithoven","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"joi180121r20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1053\/j.ajkd.2017.08.020","article-title":"Development of the autosomal dominant polycystic kidney disease impact scale: a new health-related quality-of-life instrument.","volume":"71","author":"Oberdhan","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"joi180121r21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40264-016-0486-x","article-title":"Hepatic cyst infection during use of the somatostatin analog lanreotide in autosomal dominant polycystic kidney disease: an interim analysis of the randomized open-label multicenter DIPAK-1 study.","volume":"40","author":"Lantinga","year":"2017","journal-title":"Drug Saf"},{"issue":"5","key":"joi180121r22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1046\/j.1523-1755.2002.00320.x","article-title":"Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release.","volume":"61","author":"Schmidt","year":"2002","journal-title":"Kidney Int"},{"issue":"26","key":"joi180121r23","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM198912283212601","article-title":"The effect of protein restriction on the progression of renal insufficiency.","volume":"321","author":"Ihle","year":"1989","journal-title":"N Engl J Med"},{"issue":"5","key":"joi180121r24","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/0197-2456(91)90069-X","article-title":"Design and statistical issues of the modification of diet in renal disease trial.","volume":"12","author":"Beck","year":"1991","journal-title":"Control Clin Trials"},{"issue":"19","key":"joi180121r25","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"issue":"9903","key":"joi180121r26","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"11","key":"joi180121r27","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrneph.2016.135","article-title":"The importance of total kidney volume in evaluating progression of polycystic kidney disease.","volume":"12","author":"Grantham","year":"2016","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"joi180121r28","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance.","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"issue":"8","key":"joi180121r29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney.","volume":"56","author":"Bhandari","year":"2008","journal-title":"J Histochem Cytochem"},{"issue":"1-2","key":"joi180121r30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.regpep.2003.12.015","article-title":"Expression of somatostatin receptors 1 and 2 in the adult mouse kidney.","volume":"119","author":"Bates","year":"2004","journal-title":"Regul Pept"},{"issue":"1","key":"joi180121r31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1523-1755.2003.00716.x","article-title":"Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules.","volume":"63","author":"Bates","year":"2003","journal-title":"Kidney Int"},{"issue":"11","key":"joi180121r32","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"joi180121r33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-015-0413-y","article-title":"Pasireotide in acromegaly: a review.","volume":"75","author":"McKeage","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"joi180121r34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jhep.2013.03.004","article-title":"Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.","volume":"59","author":"Chrispijn","year":"2013","journal-title":"J Hepatol"},{"issue":"9","key":"joi180121r35","doi-asserted-by":"publisher","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"25","key":"joi180121r36","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease.","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"joi180121r37","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease.","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"joi180121r38","doi-asserted-by":"publisher","first-page":"F701","DOI":"10.1152\/ajprenal.00656.2013","article-title":"Regulation of nephron water and electrolyte transport by adenylyl cyclases.","volume":"306","author":"Rieg","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"2","key":"joi180121r39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00424-012-1129-4","article-title":"Cell biology of vasopressin-regulated aquaporin-2 trafficking.","volume":"464","author":"Moeller","year":"2012","journal-title":"Pflugers Arch"},{"issue":"9","key":"joi180121r40","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease.","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"joi180121r13","first-page":"1661","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.","volume-title":"Gastroenterology","author":"van Keimpema","year":"2009"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2710504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:02:50Z","timestamp":1775253770000},"score":1,"resource":{"primary":{"URL":"http:\/\/jama.jamanetwork.com\/article.aspx?doi=10.1001\/jama.2018.15870"}},"subtitle":["The DIPAK 1 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2018,11,20]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2018.15870","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734307354.793554097","asserted-by":"object"}]},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,20]]}}}